Markets
Security ▼ | Price | % | Buy | Sell | Target price | Potential |
---|---|---|---|---|---|---|
Oragenics Inc. |
€7.60
09.02.24 |
- | 1 | 16 | €8.00 | 5.319% |
Optibiotix Health plc |
€0.25
16.07.24 |
-9.490% | 0 | 0 | - | - |
Opsens Inc |
€1.72
18.08.21 |
-0.580% | 0 | 0 | - | - |
Opko Health Inc. |
€1.27
16.07.24 |
2.150% | 0 | 0 | - | - |
Onxeo S.A. |
€0.099
16.07.24 |
10.330% | 0 | 0 | - | - |
Ono Pharmaceutical Co Ltd |
€13.10
16.07.24 |
-2.260% | 0 | 0 | - | - |
Oncotherapy Science Inc. |
€0.17
16.07.24 |
10.830% | 0 | 0 | - | - |
Oncopeptides AB |
€0.23
16.07.24 |
-1.340% | 1 | 0 | €1.00 | 339.560% |
Onconova Therapeutics Inc |
€0.39
15.07.24 |
7.260% | 1 | 0 | €3.00 | 669.231% |
Oncolytics Biotech |
€1.61
18.08.21 |
-4.730% | 7 | 0 | €4.63 | 187.391% |
Oncolys Biopharma Inc. |
€9.20
18.08.21 |
2.790% | 0 | 0 | - | - |
Oncodesign S.A. |
€14.28
09.12.22 |
-0.830% | 0 | 0 | - | - |
OncoCyte Corp |
€0.18
12.11.23 |
-3.610% | 0 | 0 | - | - |
Oncimmune Holdings PLC |
€0.12
16.07.24 |
4.500% | 0 | 0 | - | - |
Omnicell Inc. |
€25.00
16.07.24 |
3.310% | 3 | 2 | €35.45 | 41.816% |
Omeros Corp. |
€4.54
16.07.24 |
12.720% | 2 | 4 | - | - |
Omega Diagnostics Group plc |
€0.040
16.07.24 |
-3.660% | 0 | 0 | - | - |
Olympus Corp. |
€15.45
15.07.24 |
-0.970% | 4 | 2 | €17.50 | 13.269% |
Olainfarm AS |
€8.76
03.01.22 |
-1.130% | 0 | 0 | - | - |
Ocuphire Pharma Inc. |
€1.79
16.07.24 |
-1.480% | 16 | 1 | €3.50 | 95.749% |
Ocular Therapeutix Inc. |
€6.20
13:29 |
-19.400% | 30 | 4 | €10.50 | 69.355% |
Oasmia Pharmaceutical |
-
- |
- | 0 | 0 | - | - |
Nymox Pharmaceutical Corp. |
€0.23
06.07.23 |
5.410% | 0 | 0 | - | - |
Nxstage Medical |
-
- |
- | 0 | 0 | - | - |
Nuwellis Inc. |
€0.11
25.03.23 |
- | 0 | 0 | - | - |
Nuvo Pharmaceuticals Inc. |
€0.90
16.03.23 |
-1.640% | 0 | 0 | - | - |
Nuvectra Corp |
€0.10
13.12.19 |
-23.080% | 0 | 0 | - | - |
Nuvasive Inc. |
€36.60
20.11.23 |
0.510% | 0 | 0 | - | - |
Nuformix |
€0.001
16.07.24 |
- | 0 | 0 | - | - |
Novo Nordisk A/S ADR |
€124.00
13:27 |
-4.250% | 39 | 1 | €150.00 | 20.968% |